US Supreme Court Set To Review Biosimilar Rule

The US Supreme Court is set to review a biosimilar rule which forces biosimilar companies to wait six months after FDA approval before launching follow-on products. The Supreme Court’s decision will have an immediate impact on the US biosimilar industry. The court’s decision to take up the case has surprised some analysts because relatively few biosimilars have come to market in the US.

Read the source article at RAPS.org